featured
Berzosertib Plus Gemcitabine vs Gemcitabine Alone in Platinum-Resistant High-Grade Serous Ovarian Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Berzosertib Plus Gemcitabine Versus Gemcitabine Alone in Platinum-Resistant High-Grade Serous Ovarian Cancer: A Multicentre, Open-Label, Randomised, Phase 2 Trial
Lancet Oncol 2020 Jun 15;[EPub Ahead of Print], PA Konstantinopoulos, SC Cheng, AE Wahner Hendrickson, RT Penson, ST Schumer, LA Doyle, EK Lee, EC Kohn, LR Duska, MA Crispens, AB Olawaiye, IS Winer, LM Barroilhet, S Fu, MT McHale, RJ Schilder, A Färkkilä, D Chowdhury, J Curtis, RS Quinn, B Bowes, AD D'Andrea, GI Shapiro, UA MatulonisFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.